GeneHealth - Your precision medicine

Autosomal Recessive Limb-girdle Muscular Dystrophy Type 2a

Disease Details

Family Health Simplified

Buy Membership

Description: Autosomal recessive limb-girdle muscular dystrophy type 2A is a genetic disorder characterized by progressive muscle weakness and wasting, primarily affecting the shoulder and hip areas.
Type: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is inherited in an autosomal recessive manner.
Signs And Symptoms: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is characterized by progressive muscle weakness and wasting, primarily affecting the muscles around the hips and shoulders. Signs and symptoms usually manifest in late childhood to early adulthood and may include:

- Difficulty walking or running
- Trouble climbing stairs
- Gower's sign (using hands to push off knees to stand up)
- Muscle cramps
- Muscle contractures (shortening of muscles)
- Scapular winging (protrusion of shoulder blades)
- Difficulty lifting arms

As the disease progresses, it may lead to wheelchair dependency. However, cognitive function and life expectancy are generally not affected.
Prognosis: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) typically has a variable prognosis, largely depending on the severity of the symptoms and the rate of disease progression. Generally, individuals with LGMD2A experience progressive muscle weakness, particularly in the muscles around the hips and shoulders. Over time, this can lead to difficulty with walking, climbing stairs, and other mobility issues. Some patients may lose the ability to walk and become wheelchair-dependent. Respiratory and cardiac complications are less common compared to other types of muscular dystrophy but can occur. Life expectancy can be near normal if significant respiratory or cardiac issues do not develop. Regular monitoring and supportive care, including physical therapy, orthopedic interventions, and respiratory management, are crucial in managing the disease and improving quality of life.
Onset: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) typically has an onset in late childhood to early adulthood, usually between ages 8 and 15.
Prevalence: The prevalence of autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) varies by population but is generally considered rare. Estimates suggest a prevalence of approximately 1 in 100,000 to 1 in 200,000 individuals worldwide.
Epidemiology: Autosomal Recessive Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A), also known as calpainopathy, is a rare genetic disorder. Exact prevalence rates vary, but it generally occurs in about 1-9 cases per 1,000,000 individuals worldwide. The disorder affects both genders equally and can present in various ethnic groups. LGMD2A is caused by mutations in the CAPN3 gene, which provides instructions for making the enzyme calpain-3, and it typically manifests in adolescence to early adulthood.
Intractability: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is generally considered to be intractable as there is currently no cure for the disease. Management focuses on symptomatic treatment, physical therapy, and supportive care to improve the quality of life and delay progression.
Disease Severity: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is typically characterized by progressive muscle weakness and wasting, primarily affecting the muscles around the hips and shoulders (the limb-girdle area). The severity of the disease can vary, but it often leads to significant disability and loss of ambulation within a few decades after onset. Respiratory involvement is less common, but can occur in later stages. The progression and severity can be influenced by the specific genetic mutations present.
Healthcare Professionals: Disease Ontology ID - DOID:0110275
Pathophysiology: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene, which encodes the enzyme calpain-3. Calpain-3 is crucial for muscle fiber repair and maintenance. Mutations in this gene lead to a dysfunctional or absent enzyme, resulting in progressive muscle degeneration and weakness, primarily affecting the shoulder and pelvic girdle muscles.
Carrier Status: Carriers of autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) inherit one mutated copy of the CAPN3 gene from one parent but do not exhibit symptoms of the disease. These carriers can pass the mutated gene to their offspring. For a child to be affected by LGMD2A, they must inherit two mutated copies of the CAPN3 gene, one from each parent.
Mechanism: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene, which encodes calpain-3, a calcium-dependent cysteine protease.

### Mechanism:
- **Genetic Mutation:** Mutations in the CAPN3 gene lead to the production of a dysfunctional or nonfunctional calpain-3 enzyme.
- **Protease Dysfunction:** Calpain-3 is crucial for muscle fiber stability and repair. Its dysfunction disrupts the normal proteolytic processes necessary for muscle maintenance and repair.

### Molecular Mechanisms:
- **Calcium Regulation:** Calpain-3 activity is regulated by calcium ions. Mutations may affect the enzyme's ability to bind calcium, impairing its function.
- **Muscle Fiber Integrity:** The protease normally processes various substrates involved in maintaining cytoskeletal integrity and signal transduction in muscle fibers. Loss of function leads to accumulated protein damage and subsequent muscle fiber degradation.
- **Muscle Atrophy and Weakness:** The ongoing cycle of damage without proper repair leads to progressive muscle atrophy and weakness, characteristic of LGMD2A.

Overall, the molecular disruption of calpain-3 function and the subsequent failure to maintain muscle integrity underpin the pathology of LGMD2A.
Treatment: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene, which encodes the protein calpain-3. Currently, there is no cure for LGMD2A, and treatment focuses on managing symptoms and improving quality of life.

Management strategies include:

1. **Physical Therapy**: Regular exercise and physiotherapy to maintain muscle strength and flexibility.
2. **Orthopedic Devices**: Braces or other supportive devices to assist with mobility.
3. **Medications**: Pain management and possibly medications to manage muscle spasms.
4. **Respiratory Care**: Monitoring and treatment of respiratory function if it becomes compromised.
5. **Nutrition**: Proper diet to prevent obesity, which can stress weakened muscles.
6. **Regular Monitoring**: Ongoing assessment by a multidisciplinary team to address emerging needs.

Collaboration with specialists such as neurologists, orthopedic surgeons, and physical therapists is essential in managing the condition effectively.
Compassionate Use Treatment: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene. Compassionate use, off-label, or experimental treatments for LGMD2A may include:

1. **Gene Therapy:** Experimental gene therapy approaches aim to correct the underlying genetic defect by delivering a functional version of the CAPN3 gene to affected muscle cells.

2. **Myostatin Inhibitors:** Myostatin is a protein that inhibits muscle growth. Inhibitors or blockers of myostatin are being studied to promote muscle growth and improve muscle strength in muscular dystrophies.

3. **Exon Skipping Therapy:** This technique may allow cells to skip over faulty parts of the gene, potentially producing a functional protein despite the mutation. This type of therapy is still largely in the experimental phase for LGMD2A.

4. **Stem Cell Therapy:** Experimental treatments are exploring the use of stem cells to regenerate damaged muscle tissue or introduce healthy muscle cells into patients.

5. **Anti-inflammatory Drugs:** Off-label use of existing anti-inflammatory medications like corticosteroids can help manage symptoms by reducing muscle inflammation and damage.

6. **Supportive Treatments:** Physiotherapy, use of assistive devices, and other supportive treatments are often used to manage symptoms and improve quality of life, although they do not address the underlying genetic cause.

Patients should consult with medical professionals and participate in clinical trials where appropriate, as these treatments are still largely in the research and development phases.
Lifestyle Recommendations: For individuals with autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A):

1. **Physical Activity**: Engage in low-impact exercises like swimming or cycling to maintain muscle strength and cardiovascular health. Avoid high-resistance or high-impact activities that could cause muscle damage.

2. **Physical Therapy**: Regular sessions with a physical therapist can help in maintaining mobility and managing symptoms. Stretching and gentle strength training exercises may be recommended.

3. **Balanced Diet**: Consume a nutritious diet rich in proteins, vitamins, and minerals to support overall health. Avoid excessive calorie intake to prevent obesity, which can strain weakened muscles.

4. **Assistive Devices**: Use mobility aids such as braces, canes, or wheelchairs if needed to maintain independence and reduce the risk of falls.

5. **Regular Monitoring**: Have regular check-ups with a neurologist and other healthcare professionals to monitor disease progression and adjust treatment plans accordingly.

6. **Respiratory Care**: Monitor respiratory function regularly, as muscle weakness can affect breathing over time. Pulmonary interventions may be necessary.

7. **Cardiac Health**: Regular cardiac evaluations are important since some types of muscular dystrophy can affect the heart.

8. **Mental Health**: Psychological support or counseling can help handle the emotional challenges associated with the disease.

9. **Routine Vaccinations**: Stay up-to-date with vaccinations to prevent infections that could exacerbate the condition.

10. **Avoidance of Prolonged Immobility**: Prolonged periods of immobility should be avoided as they may lead to worsening muscle weakness and joint contractures.

These lifestyle recommendations aim to enhance quality of life and manage the symptoms associated with LGMD2A. Consult healthcare professionals for personalized advice.
Medication: For autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A), there are currently no specific medications that can cure the disease. Management primarily focuses on supportive treatments to improve quality of life and maintain muscle function. This may include physical therapy, occupational therapy, and the use of assistive devices. In some cases, corticosteroids are used to manage symptoms, but their effectiveness can vary. Genetic counseling is also recommended for affected individuals and their families. Researchers are actively pursuing gene therapy and other potential treatments.
Repurposable Drugs: For autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A), caused by mutations in the CAPN3 gene encoding the calpain-3 protein, there are currently no specific repurposable drugs that have been proven effective in clinical trials. Management focuses on symptom relief and supportive care, such as physical therapy, orthopedic interventions, and respiratory support. Research is ongoing to identify potential drug candidates and innovative therapies. Comprehensive consultation with a medical specialist is recommended for the latest treatment options.
Metabolites: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene encoding the protein calpain-3. Primary metabolites and biomarkers directly linked to LGMD2A can be elusive due to the complexity of the disease mechanisms. However, general biomarkers that may be assessed in muscle disorders include:

1. **Creatine kinase (CK):** Elevated serum CK levels are typically observed and indicate muscle damage.
2. **Lactic acid:** Increased levels can suggest muscle cell dysfunction.
3. **Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST):** These liver enzymes can also be elevated and may reflect muscle damage.

Further specific metabolites related to calpain-3 dysfunction in LGMD2A are still under investigation and are less well-characterized.
Nutraceuticals: There are no established nutraceuticals specifically proven to treat or manage autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A). The focus for managing LGMD2A is generally on physical therapy, supportive devices, and symptomatic treatments rather than specific dietary supplements or nutraceuticals. Consultation with a healthcare provider for personalized management plans is recommended.
Peptides: Autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is primarily caused by mutations in the CAPN3 gene, which encodes calpain-3, a muscle-specific protease. Peptides derived from or relating to calpain-3 could potentially be significant in research contexts, such as understanding disease mechanisms or developing therapeutic strategies. However, "nan" typically does not hold specific clinical relevance within the context provided. If "nan" is intended to refer to "nanotechnology" or something similar in your question, it might relate to novel therapeutic approaches or delivery systems for treatments, but further clarification would be needed.